Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in Phase III for Chemotherapy Induced Anemia. According to GlobalData, Phase III drugs for Chemotherapy Induced Anemia have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ferric carboxymaltose’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ferric carboxymaltose overview

Ferric carboxymaltose (Ferinject, Injectafer, Renegy, Feryxa) is an iron replacement product. It is formulated as solution for intravenous route of administration. Ferric carboxymaltose is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is under development for the treatment of restless legs syndrome, chemotherapy induced anemia, heart failure with iron deficiency and reduced ejection fraction.

It was also under development for the treatment of iron deficiency anemia.

Vifor Pharma Management overview

Vifor Pharma Management (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines for unmet medical needs of the gastrointestinal tract. It operates production plants in Portugal and Switzerland, and carries out business through subsidiaries. Vifor Pharma is headquartered in St. Gallen, Switzerland.

For a complete picture of Ferric carboxymaltose’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.